| Citation: |
SUN Lu, TIAN Hu, CHEN Shuai, LIANG Lifeng. Application of Wenshen Formula in patients with spleen and kidney yang deficiency syndrome after operation of Hashimoto's thyroiditis complicated with differentiated thyroid carcinoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 118-122. DOI: 10.7619/jcmp.20231076
|
To observe the application effect of Wenshen Formula in treating patients with spleen and kidney yang deficiency syndrome after operation of Hashimoto's thyroiditis complicated with differentiated thyroid carcinoma (DTC).
Ninety-eight patients with Hashimoto's thyroiditis combined with spleen-kidney Yang deficiency syndrome after DTC surgery admitted to the hospital from November 2019 to February 2022 were included in this study, and were divided into observation group (n=49) and control group (n=49) according to random number table method. Both groups were treated with thyroid stimulating hormone (TSH) inhibition therapy, and the control group was treated with Jinshuibao Capsule on this basis. Combined with the principle of warming kidney, strengthening spleen and removing dampness. in treatment of spleen and kidney yang deficiency syndrome by Professor Chen Ruquan, a famous TCM doctor, the patients in the observation group were treated with self-made Wenshen Formula. The clinical efficacy, TCM symptom score, thyroid hormone indexes[serum free triiodothyronine (FT3), serum free thyroxine (FT4), TSH]levels of the two groups were observed after treatment, and the occurrence of adverse reactions of the two groups during treatment were recorded.
After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05). The observation group had lower scores of aversion to chills of four limbs, fatigue, dizziness, blurred vision, dry mouth and throat, lack of breath and laziness to speak, chest tightness and shortness of breath than the control group (P < 0.05). Compared with control group, the level of TSH in the observation group was lower, and the levels of serum FT3 and FT4 were higher (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05).
Wenshen Formula has a good therapeutic effect in patients with Hashimoto's thyroiditis complicated with DTC differentiated as spleen and kidney Yang deficiency syndrome after surgery, can significantly improve the clinical symptoms, regulate the thyroid hormone level, improve thyroid function, and has no increase in the incidence of adverse reactions.
| [1] |
武百强. 益气养阴汤治疗分化型甲状腺癌术后气阴两虚证40例[J]. 河南中医, 2019, 39(5): 731-734. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201905021.htm
|
| [2] |
陈春光, 许萍. 养阴散结汤对分化型甲状腺癌患儿行甲状腺次全切除术后T淋巴细胞亚群的影响[J]. 中医学报, 2019, 34(1): 126-130. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK201901030.htm
|
| [3] |
PARK H, PARK J, YOO H, et al. Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy[J]. Clin Endocrinol (Oxf), 2022, 97(1): 130-136. doi: 10.1111/cen.14698
|
| [4] |
郝珊瑚, 纪立秋, 王治国, 等. 黄芪注射液联合131I核素治疗分化型甲状腺癌临床研究[J]. 西部中医药, 2020, 33(3): 97-100. https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY202003027.htm
|
| [5] |
中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写. 中国甲状腺疾病诊治指南: 甲状腺炎[J]. 中华内科杂志, 2008, 47(9): 784-788. doi: 10.3321/j.issn:0578-1426.2008.09.032
|
| [6] |
葛均波, 徐永健, 王辰. 内科学[M]. 9版. 北京: 人民卫生出版社, 2018: 696-698.
|
| [7] |
郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 226.
|
| [8] |
傅强, 黄学阳, 王建春, 等. 养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J]. 陕西中医, 2022, 43(8): 1029-1031, 1036. doi: 10.3969/j.issn.1000-7369.2022.08.009
|
| [9] |
段姗姗, 王永恒, 熊武, 等. 加味当归建中汤联合优甲乐对分化型甲状腺癌的临床观察[J]. 世界中医药, 2020, 15(24): 3826-3830, 3835. doi: 10.3969/j.issn.1673-7202.2020.24.020
|
| [10] |
王鑫, 宋清斌, 徐冬冬, 等. 术后首次放射性碘治疗时机的选择对分化型甲状腺癌早期疗效的影响[J]. 中国医科大学学报, 2019, 48(4): 359-362, 369. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201904017.htm
|
| [11] |
覃佐涛, 韩庆龙, 陈继东. 陈如泉治疗甲状腺癌术后经验[J]. 湖北中医药大学学报, 2022, 24(4): 116-119. doi: 10.3969/j.issn.1008-987x.2022.04.34
|
| [12] |
梁优, 刘兆龙, 杨乐, 等. 会厌逐瘀汤对分化型甲状腺癌术后康复的影响研究[J]. 现代中西医结合杂志, 2022, 31(11): 1497-1501. doi: 10.3969/j.issn.1008-8849.2022.11.008
|
| [13] |
欧阳文奇, 陈继东, 向楠, 等. 陈如泉辨证分型治疗乳头状甲状腺癌术后[J]. 中医药临床杂志, 2020, 32(1): 24-26. https://www.cnki.com.cn/Article/CJFDTOTAL-AHLC202001006.htm
|
| [14] |
陈号, 杨文娟, 秦书彦, 等. 疏肝温肾方对桥本甲状腺炎并发亚临床甲状腺功能减退症患者甲状腺功能和甲状腺自身抗体的影响[J]. 河北中医, 2021, 43(3): 416-419. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY202103014.htm
|
| [15] |
张丹丹. 健脾温肾汤联合甲状腺激素替代疗法对老年亚临床甲状腺功能减退症患者甲状腺激素、心脏结构功能和动脉硬化的影响[J]. 现代中西医结合杂志, 2019, 28(27): 3032-3036. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201927017.htm
|
| [16] |
吴捷, 王欢, 梁昌平, 等. 血清刺激性甲状腺球蛋白水平在分化型甲状腺癌诊断及预后预测中的价值[J]. 实用临床医药杂志, 2021, 25(10): 57-61. doi: 10.7619/jcmp.20210124
|
| [17] |
张云亭, 刘羽茜, 蒋宗蓥, 等. 参苓白术散通过TLR4/MyD88通路对Lewis肺癌小鼠肿瘤凋亡的干预作用[J]. 中医药导报, 2021, 27(11): 41-45, 63. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB202111008.htm
|
| [18] |
王丹, 王建, 高思佳, 等. 基于网络药理学预测黄芪抗肝癌的有效成分及其潜在靶点[J]. 中国医院用药评价与分析, 2019, 19(1): 6-9. https://www.cnki.com.cn/Article/CJFDTOTAL-YYPF201901002.htm
|
| [19] |
周莹, 刘华钢, 孙悦文, 等. 二去水卫矛醇对人非小细胞肺癌H460细胞体内抗癌活性及其机制研究[J]. 广西医科大学学报, 2022, 39(2): 215-220. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYD202202006.htm
|
| [20] |
杨彩哲, 朱迪. 军事飞行人员甲状腺功能亢进症个别评定指南(2022)[J]. 空军军医大学学报, 2022, 43(6): 550-553, 558. https://www.cnki.com.cn/Article/CJFDTOTAL-DSJY202206006.htm
|
| [21] |
姚礼, 严轶群, 汪加宽, 等. 甲状腺癌颈侧区淋巴结清扫术后甲状腺功能、甲状腺球蛋白抗体、甲状腺球蛋白的变化[J]. 实用临床医药杂志, 2018, 22(7): 60-62, 66. doi: 10.7619/jcmp.201807016
|
| [22] |
陈伟, 李晓艳, 董频, 等. 血清促甲状腺激素水平与分化型甲状腺癌的相关性研究[J]. 中国眼耳鼻喉科杂志, 2019, 19(5): 332-336. https://www.cnki.com.cn/Article/CJFDTOTAL-YRBH201905012.htm
|
| [23] |
张俊林. 疏肝健脾温肾方联合左甲状腺素钠片治疗桥本甲状腺炎合并亚临床甲状腺功能减退48例[J]. 中医研究, 2017, 30(2): 24-26. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYJ201702011.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: